Literature DB >> 16041805

Decreased density of muscarinic receptors in the superior temporal gyrusin schizophrenia.

Chao Deng1, Xu-Feng Huang.   

Abstract

Recent studies have indicated that muscarinic receptors are involved in the pathophysiology in schizophrenia, particularly in cognitive deficits. The superior temporal gyrus (STG) is an area that has also been strongly implicated in the pathophysiology of schizophrenia. Therefore, in this study, we investigated the binding density of two muscarinic antagonists, [(3)H]pirenzepine and [(3)H]AF-DX 384, in the STG of schizophrenia patients compared with controls. A significant decrease (44% in the superficial layers and 48% in the deep layers, P<0.01) in binding density of [(3)H]pirenzepine was observed in schizophrenia patients, which suggested a reduction of muscarinic M1 and M4 receptor densities in the STG of schizophrenia patients. A tendency toward decreased [(3)H]AF-DX 384 binding density (34%, P=0.09) was also observed in schizophrenia patients compared with controls. Because of the positive correlation between [(3)H]pirenzepine and [(3)H]AF-DX 384 binding, and, insofar as both ligands have high affinities for the M4 receptor, the involvement of M4 receptor alteration is also suggested in the STG in schizophrenia. These results suggest that changes of the muscarinic receptors M1 and M4 might contribute to the STG pathology in schizophrenia. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16041805     DOI: 10.1002/jnr.20600

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  29 in total

Review 1.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

2.  Increased density of GABAA receptors in the superior temporal gyrus in schizophrenia.

Authors:  Chao Deng; Xu-Feng Huang
Journal:  Exp Brain Res       Date:  2005-12-16       Impact factor: 1.972

3.  Changes in BQCA Allosteric Modulation of [(3)H]NMS Binding to Human Cortex within Schizophrenia and by Divalent Cations.

Authors:  Brian Dean; Shaun Hopper; P Jeffrey Conn; Elizabeth Scarr
Journal:  Neuropsychopharmacology       Date:  2015-10-29       Impact factor: 7.853

4.  Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's Disease.

Authors:  Ditte Dencker; Morgane Thomsen; Gitta Wörtwein; Pia Weikop; Yinghong Cui; Jongrye Jeon; Jürgen Wess; Anders Fink-Jensen
Journal:  ACS Chem Neurosci       Date:  2012       Impact factor: 4.418

Review 5.  Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor.

Authors:  Katrina Weston-Green; Xu-Feng Huang; Chao Deng
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

6.  Modulation of prepulse inhibition through both M(1) and M (4) muscarinic receptors in mice.

Authors:  Morgane Thomsen; Jürgen Wess; Brian S Fulton; Anders Fink-Jensen; S Barak Caine
Journal:  Psychopharmacology (Berl)       Date:  2009-12-15       Impact factor: 4.530

Review 7.  M1 muscarinic receptor for the development of auditory cortical function.

Authors:  Karalee K Shideler; Jun Yan
Journal:  Mol Brain       Date:  2010-10-22       Impact factor: 4.041

8.  Prefrontal gray matter morphology mediates the association between serum anticholinergicity and cognitive functioning in early course schizophrenia.

Authors:  Jessica A Wojtalik; Shaun M Eack; Bruce G Pollock; Matcheri S Keshavan
Journal:  Psychiatry Res       Date:  2012-11-15       Impact factor: 3.222

9.  Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.

Authors:  Katie Leach; Richard E Loiacono; Christian C Felder; David L McKinzie; Adrian Mogg; David B Shaw; Patrick M Sexton; Arthur Christopoulos
Journal:  Neuropsychopharmacology       Date:  2009-11-25       Impact factor: 7.853

10.  Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test.

Authors:  Jared W Young; Jessica M Meves; Mark A Geyer
Journal:  Behav Brain Res       Date:  2012-11-29       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.